Title:  The Impact of Psychedelic Medications in Mental Health Treatment and Considerations in Life Insurance Underwriting

             Psychedelic medications are re-emerging as potent tools in the treatment of various mental health disorders, supported by a growing body of scientific evidence. With careful management of their risk, they hold the potential to offer profound benefits for individuals suffering from various psychiatric conditions. This paper explores the historical context, current clinical applications, and underwriting recommendations for psychedelic therapy.

History and Development of Psychedelic Therapy

            The exploration of psychedelics as therapeutic agents began in the mid-20^th century, marking a significant era in psychiatric research. In 1943, Swiss chemist Albert Hofmann discovered the psychoactive properties of lysergic acid diethylamide (LSD), which led to a wave of enthusiasm in the scientific community. LSD was initially studied for its potential to unlock insight into the human mind and to treat a range of psychiatric conditions including depression, anxiety, and substance abuse disorders. Research from this period suggested that these substances could facilitate profound psychological breakthroughs and catalyze therapeutic processes that were otherwise difficult to achieve through traditional methods. A 1950s landmark study by Humphry Osmond and Abram Hoffer demonstrated promising results in using LSD to treat alcoholism, reporting that a single high-dose session could lead to long-term abstinence in a significant number of patients (Osmond, 1957).

            Despite these early successes, the use of psychedelics in medicine became highly controversial by the late 1960s. The widespread recreational use of these substances, coupled with sensational media portrayals and rising sociopolitical tensions, led to public backlash and stringent regulatory actions. By 1970, the U.S. government classified LSD and other psychedelics as Schedule I substances under the Controlled Substances Act, which effectively halted most clinical research and reclassified these compounds as having no accepted medical use and high potential for abuse.

            Pioneering studies such as those led by Dr. Roland Griffiths at Johns Hopkins University, reignited scientific curiosity by demonstrating the potential of psilocybin to alleviate symptoms of anxiety and depression (Griffiths et al., 2006). This modern era of research has sparked a re-evaluation of the therapeutic potential of psychedelics, setting the stage for a new wave of clinical trials and a broader acceptance within the medical community.

The Therapeutic Potential of Psychedelic Medications

The therapeutic potential of psychedelics is rooted in their unique ability to modulate brain function and connectivity, leading to profound alterations in perception, cognition, and mood. At the molecular level, most classical psychedelics, such as psilocybin, LSD, and DMT, act primarily as agonists at the serotonin 2A receptor sites in the brain. Activation of these receptors enhances the release of neurotransmitters like glutamate, which plays a key role in synaptic plasticity and the formation of new neural connections (Vollenweider & Kometer, 2010). This activity is believed to disrupt the normal communication patterns between different brain regions, particularly within the default mode network (DMN). By dampening the DMN’s activity, psychedelics facilitate a state of “ego dissolution,” which many users describe as a sense of unity or interconnectedness with their surroundings (Carhart-Harris et al., 2012).

This profound alteration in brain connectivity allows for a temporary reorganization of neural pathways, enabling individuals to break free from entrenched patterns of thinking and behavior that underpin many psychiatric conditions. In patients with depression, the overactivity of the DMN is often correlated with persistent negative rumination and self-critical thought patterns. Psychedelic-induced disruption of this network can provide a cognitive reset, offering a fresh perspective that supports emotional healing and cognitive flexibility (Carhart-Harris & Friston, 2019). Psychedelics like MDMA primarily act through the release of large amounts of serotonin, dopamine, and norepinephrine, which enhances emotional processing and reduces fear responses, making it particularly effective in the context of PTSD therapy (Mithoefer et al., 2011).

Recent neuroimaging studies have shown that psychedelics promote long-term changes in brain structure and function. Psilocybin has been found to increase connectivity across various brain networks and enhance neuroplasticity, the brain’s ability to reorganize itself by forming new neural connections (Ly et al., 2018). These findings underscore the potential of psychedelics to facilitate deep, lasting changes in mental health by targeting fundamental processes at the neurobiological level.

Current Clinical Applications

In recent years, the therapeutic potential of psychedelics has been rigorously examined through a series of controlled clinical trials, revealing their efficacy in treating a variety of mental health conditions. One of the most notable applications is in the treatment of depression, particularly treatment-resistant depression (TRD). A pivotal study conducted by Carhart-Harris and colleagues (2018) demonstrated that psilocybin therapy led to significant and sustained reductions in depressive symptoms in patients who were unresponsive to conventional treatments. In a study by Ross et al. (2016), psilocybin was shown to alleviate anxiety and depression in patients facing life-threatening cancer diagnoses, with many participants experiencing a newfound sense of peace and reduced existential distress.

Psychedelics have also shown promise in treating Post-Traumatic Stress Disorder (PTSD).  MDMA-assisted therapy has emerged as a particularly effective intervention. In a landmark Phase 3 clinical trial led by Mitchell et al. (2021), participants with severe, chronic PTSD who received MDMA-assisted therapy exhibited substantial reductions in PTSD symptoms compared to those receiving a placebo.

Psychedelics are also being explored as a novel treatment for substance use disorders. Johnson et al. (2014) found that psilocybin-assisted therapy significantly increased the rates of smoking cessation among participants, with a substantial proportion remaining abstinent over long-term follow-up periods. The mechanism behind this success is thought to be linked to the way psychedelics disrupt rigid patterns of behavior and thought, providing a fresh perspective that empowers individuals to break free from addiction cycles. Similarly, psilocybin is currently being investigated for its potential benefits in conditions such as anorexia nervosa, obsessive-compulsive disorder (OCD), and chronic pain (Meade, et. al., 2022). Additionally, the exploration of microdosing – taking sub-perceptual doses of psychedelics – offers intriguing possibilities for enhancing cognitive function and emotional well-being without the intense psychoactive effects associated with traditional therapeutic dosages.

Recommendations for Life Insurance Underwriters

            The increasing acceptance and integration of psychedelic-assisted therapies into mental health treatment poses unique challenges and opportunities for life insurance underwriters. Distinguishing between recreational and medically supervised therapy will be key in underwriting these cases. Clinical settings offer controlled environments that mitigate risks associated with uncontrolled use. Other factors for consideration when underwriting these files include the type of psychedelic prescribed, dosage used, age when psychedelic therapy began, reason for therapy, frequency of use, and personal history of substance abuse.

It is crucial to assess the therapeutic outcomes of psychedelic treatments on a case-by-case basis. Psychedelics are not considered first-line therapy for any mental health disorder, so their use generally points toward the presence of more severe disease. Underwriters should consider evidence of significant and sustained improvements in mental health, as documented by clinical reports and follow-up evaluations. For example, applicants who have successfully undergone psychedelic therapy for treatment-resistant depression or PTSD might present a lower risk profile compared to those with unmanaged or severe symptoms. Stability in mental health post-therapy, as indicated by continued engagement in follow-up care and the absence of adverse events, should be a key factor in underwriting decisions.

            Comprehensive medical and psychological evaluations should be integrated into the underwriting process. These evaluations can provide insights into the applicant’s overall mental health, including any residual effects or potential relapses following psychedelic therapy. Underwriting red flags can include varying dosages, dosages above the recommended microdose, concurrent use of more than one type of psychedelic, frequency more than recommended by the prescriber, treatment received outside of an authorized facility, personal history of substance abuse, and risky behavior (e.g. gambling, financial difficulties, personal or work instability).

            Underwriters should develop risk stratification models that reflect the unique aspects of psychedelic therapies. This includes considering factors such as the specific psychedelic substance used, the frequency and duration of treatment, the presence of any pre-existing conditions, and the applicant’s adherence to recommended therapeutic and aftercare protocols. These models can help differentiate between low-risk individuals who have responded positively to therapy and those who may still pose a higher risk due to ongoing or severe psychiatric issues.

Conclusion

 The resurgence of scientific research into psychedelics underscores their potential to facilitate profound psychological healing by leveraging their unique mechanisms of action on brain function and connectivity. Clinical trials have demonstrated their efficacy in treating a range of disorders, highlighting the significant therapeutic benefits these substances can provide under controlled conditions. Underwriters must remain flexible and work to increase their knowledge regarding these therapies as they make their way into mainstream medicine. Through thoughtful and responsible exploration, the full potential of these ancient medicines to address the pressing mental health challenges of our time can be realized.

References

Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., … & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology, 235(2), 399-408. doi:10.1007/s00213-017-4771-x.

Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., … & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138-2143. doi:10.1073/pnas.1119598109.

Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316-344. doi:10.1124/pr.118.017160.

Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187, 268–283. doi:10.1007/s00213-006-0457-5.

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2A receptor agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992. doi:10.1177/0269881114548296.

Ly, C., Greb, A. C., Cameron, L. P., Wong, R. J., Barragan, E. V., Wilson, P. C., … & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170-3182. doi:10.1016/j.celrep.2018.05.022.

Meade E, Hehir S, Rowan N, Garvey M. Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain. Journal of Fungi. 2022; 8(3):290. https://doi.org/10.3390/jof8030290

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., … & Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025-1033. doi:10.1038/s41591-021-01336-3.

Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011). The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology, 25(4), 439-452. doi:10.1177/0269881110378371.

Osmond, H. (1957). A review of the clinical effects of psychotomimetic agents. Annals of the New York Academy of Sciences, 66(3), 418-434. doi:10.1111/j.1749-6632.1957.tb40738.x.

Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., … & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165-1180. doi:10.1177/0269881116675512.

Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience, 11(9), 642-651. doi:10.1038/nrn2884.